Synageva downgraded to Neutral from Overweight at Piper Jaffray Piper Jaffray downgraded Synageva on expectations the stock will be range bound as the Phase III CESD trial progresses. The firm lowered its price target for shares to $57 from $66.
News For GEVA From The Last 14 Days
Check below for free stories on GEVA the last two weeks.
Synageva downgraded to Neutral from Overweight at JPMorgan JPMorgan downgraded Synageva citing concerns that the enrollment could be challenging for the sebelipase alfa Phase 3 trial. The firm lowered its price target for shares to $50 from $57.